General Cancer
Dual Checkpoint Blockade With Neoadjuvant Chemo Shows Benefit in Ovarian Cancer
March 27th 2023The phase 2 KGOG3046 is the first study to show survival outcomes with the dual checkpoint blockades, durvalumab and tremelimumab, combined with neoadjuvant chemotherapy for the treatment of patients with newly diagnosed advanced ovarian cancer.
Read More
Zolbetuximab/CAPOX Prolongs Survival in CLDN18.2-Positive/HER2-Negative Advanced Gastric/GEJ Cancers
March 22nd 2023FDA approval may be looming for the combination of zolbetuximab and capecitabine/oxaliplatin after primary phase 3 results were presented during the March ASCO Virtual Plenary.
Read More
Updates on Recent Advances and Treatments for Hematologic Malignancies
March 22nd 2023In an interview with Targeted Oncology, Guenther Koehne, MD, PhD, provided an overview of The Summit of Americas on Immunotherapies for Hematologic Malignancies and some of the recent and exciting advances being seen in the hematology space.
Read More
2 Clarke Drive
Cranbury, NJ 08512